Sterling IMRES
Sign in
Research articleOpen access

Dexamethasone in Hospitalized Patients with Covid-19

New England Journal of Medicine · 25 February 2021

Read at the publisher Full text on PMC
Reference library record. This work was written and published by the people and publisher named here. It is listed in the Sterling IMRES reference library for study and citation. Sterling IMRES did not author or publish it, and listing a work does not mean its authors are affiliated with the institute. Metadata verified via Crossref. How records are verified

Summary

Final report of the dexamethasone comparison in the RECOVERY platform trial among patients hospitalized with COVID-19 in the United Kingdom. The trial found lower 28-day mortality with dexamethasone among patients receiving respiratory support, and it is a prominent example of a large, pragmatic adaptive platform trial run during a pandemic.

Summary written by Sterling IMRES editors. Read the original abstract at the publisher.

Authors

Group author: The RECOVERY Collaborative Group.

Cite this work

The RECOVERY Collaborative Group. Dexamethasone in Hospitalized Patients with Covid-19. New England Journal of Medicine. 2021;384(8):693-704. doi:10.1056/NEJMoa2021436

Related research

RecruitingInterventionalPhase 3

Randomised Evaluation of COVID-19 Therapy

University of Oxford

RECOVERY is a large randomised, open-label platform trial led by the University of Oxford that has tested many treatments for patients admitted to hospital with COVID-19, and has since added influenza and community-acquired pneumonia. Its pragmatic design, with minimal data collection and a shared control group, allowed rapid answers, including the finding that dexamethasone reduced deaths. It remains a reference model for efficient trial methodology.

2020

Related publications